You just read:

Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial

News provided by

Amgen

Nov 05, 2011, 05:10 ET